Abstract 22P
Background
The purpose of this study was to evaluate the characteristics and outcomes of early breast cancer patients who underwent skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy without radiotherapy.
Methods
A total 104 patients with early breast cancer who underwent mastectomy with sentinel lymph node biopsy were identified in Korea Ansan University Hospital between 2007 and 2017. 85 total mastectomies (TM), 11 nipple areolar complex-sparing mastectomies (NSM), and 8 Skin-sparing mastectomiesm (SSM) were included. All these patients did not undergo adjuvant radiotherapy on chest wall or axillary area. We divided the patients into two groups, TM group and NSM/SSM group. We retrospectively collected clinitopathologic data for these patients. Locoregional recurrence rate, distant recurrence rate, overall recurrence free survival, and overall survival were determined. All statistical analysis was performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Median follow-up was 53 months. Fifty-five percentage of TM group patients received chemotherapy and 63.7 % of NSM/SSM patients received chemotherapy. Locoregional recurrence free survival was 95.3% vs. 78.9% in TM group and NSM/SSM group (p = 0.037). Locoregional failure rate was significantly high in NSM/SSM group than TM group. Distant recurrence free survival was 97.6% vs. 89.5% in TM group and NSM/SSM group (p = 0.128). Overall recurrence free survival was 92.9% vs. 78.9% in TM group and NSM/SSM group (p = 0.118). Overall survival was 98.8% and 94.7% in TM group and NSM/SSM group (p = 0.289). Total two deaths were observed in enrolled patients, one in TM group and another in NSM/SSM group. One death in TM group was unrelated to breast cancer and cause of death was complication from end-stage renal disease. One death in NSM/SSM group was related to breast cancer.
Conclusions
In conclusion, early breast cancer patients who underwent total mastectomy, skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy had excellent outcomes without additional axillary surgery or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract